CA2718538A1 - Quinoline derivatives as axl kinase inhibitors - Google Patents

Quinoline derivatives as axl kinase inhibitors Download PDF

Info

Publication number
CA2718538A1
CA2718538A1 CA2718538A CA2718538A CA2718538A1 CA 2718538 A1 CA2718538 A1 CA 2718538A1 CA 2718538 A CA2718538 A CA 2718538A CA 2718538 A CA2718538 A CA 2718538A CA 2718538 A1 CA2718538 A1 CA 2718538A1
Authority
CA
Canada
Prior art keywords
yloxy
phenyl
quinolin
fluoro
benzenesulfonamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2718538A
Other languages
English (en)
French (fr)
Inventor
Axel Ullrich
Pjotr Knyazev
Yixiang Zhang
Gyorgy Keri
Laszlo Orfi
Istvan Szabadkai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften
Publication of CA2718538A1 publication Critical patent/CA2718538A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2718538A 2008-04-16 2009-04-16 Quinoline derivatives as axl kinase inhibitors Abandoned CA2718538A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4539808P 2008-04-16 2008-04-16
US61/045,398 2008-04-16
PCT/EP2009/002798 WO2009127417A1 (en) 2008-04-16 2009-04-16 Quinoline derivatives as axl kinase inhibitors

Publications (1)

Publication Number Publication Date
CA2718538A1 true CA2718538A1 (en) 2009-10-22

Family

ID=40999731

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2718538A Abandoned CA2718538A1 (en) 2008-04-16 2009-04-16 Quinoline derivatives as axl kinase inhibitors

Country Status (12)

Country Link
US (1) US9206130B2 (enExample)
EP (1) EP2262772B8 (enExample)
JP (1) JP5746015B2 (enExample)
KR (1) KR101325237B1 (enExample)
CN (1) CN102131783A (enExample)
AU (1) AU2009237938A1 (enExample)
CA (1) CA2718538A1 (enExample)
ES (1) ES2391373T3 (enExample)
IL (1) IL208103A (enExample)
MX (1) MX2010011224A (enExample)
RU (1) RU2010146474A (enExample)
WO (1) WO2009127417A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2311809A1 (en) * 2009-10-16 2011-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinolinyloxyphenylsulfonamides
EP2423208A1 (en) * 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
ITRM20100537A1 (it) 2010-10-12 2012-04-12 Consiglio Nazionale Ricerche Aptamero inibitore del recettore tirosina chinasi axl per uso in terapia
DK2780338T3 (en) * 2011-11-14 2016-12-19 Ignyta Inc Uracil AS AXL- AND C-MET kinase inhibitors
NZ627586A (en) 2012-01-31 2016-08-26 Daiichi Sankyo Co Ltd Pyridone derivatives
CA2879542A1 (en) 2012-07-25 2014-01-30 Salk Institute For Biological Studies Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
CA2929188C (en) 2013-11-20 2022-08-09 Signalchem Lifesciences Corp. Quinazoline derivatives as tam family kinase inhibitors
US9873670B2 (en) 2013-11-22 2018-01-23 University Of Kentucky Research Foundation Arylquinoline and analog compounds and use thereof to treat cancer
US10233176B2 (en) 2013-11-27 2019-03-19 Signalchem Lifesciences Corporation Aminopyridine derivatives as TAM family kinase inhibitors
TWI723572B (zh) 2014-07-07 2021-04-01 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
WO2016104617A1 (ja) * 2014-12-25 2016-06-30 小野薬品工業株式会社 キノリン誘導体
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
US20190099413A1 (en) 2016-02-26 2019-04-04 Ono Pharmaceutical Co., Ltd. Drug for cancer therapy characterized in that axl inhibitor and immune checkpoint inhibitor are administered in combination
EP3436461B1 (en) 2016-03-28 2023-11-01 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
CN108250200A (zh) * 2016-12-28 2018-07-06 中国科学院上海药物研究所 一种具有Axl抑制活性的化合物及其制备和应用
PT3575293T (pt) 2017-01-26 2021-05-25 Ono Pharmaceutical Co Sal de etanossulfonato de n-{5-[(6,7-dimetoxi-4-quinolinil)oxi]-2-piridinil}-2,5-dioxo-1-fenil-1,2,5,6,7,8-hexahidro-3-quinolinocarboxamida
EP3673907A4 (en) 2017-08-23 2020-08-19 ONO Pharmaceutical Co., Ltd. CANCER TREATMENT PHARMACEUTICAL INCLUDING AX1 INHIBITOR AS AN EFFECTIVE INGREDIENT
CR20200140A (es) * 2017-08-31 2020-05-15 Abbvie Inc Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
MY208007A (en) 2017-09-27 2025-04-04 Incyte Corp Salts of pyrrolotriazine derivatives useful as tam inhibitors
JP7223998B2 (ja) 2017-10-13 2023-02-17 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
AR117600A1 (es) 2018-06-29 2021-08-18 Incyte Corp Formulaciones de un inhibidor de axl / mer
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4114401A1 (en) 2020-03-06 2023-01-11 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
MX2022014020A (es) * 2020-05-08 2023-02-16 Georgiamune Llc Moduladores de akt3.
JP2022104746A (ja) * 2020-12-29 2022-07-11 国立研究開発法人国立がん研究センター 抗がん剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
ATE253051T1 (de) 1999-01-22 2003-11-15 Kirin Brewery Chinolinderivate und chinazolinderivate
US7041691B1 (en) * 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
EP1566379A4 (en) * 2002-10-29 2005-11-09 Kirin Brewery CHINOLINE DERIVATIVES AND CHINAZOLINE DERIVATIVES AS INHIBITORS OF FLT3 AUTOPHOSPHORYLATION AND THE MEDICAL COMPOSITIONS CONTAINING THEREOF
CA2744997A1 (en) * 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
CA2619037A1 (en) * 2005-08-22 2007-03-01 Boehringer Ingelheim International Gmbh Bicyclic heterocycles medicaments comprising said compounds use and method for production thereof
US20110053931A1 (en) * 2006-06-08 2011-03-03 John Gaudino Quinoline compounds and methods of use
AU2007334402B2 (en) 2006-12-14 2014-02-13 Exelixis, Inc. Methods of using MEK inhibitors

Also Published As

Publication number Publication date
JP2011517689A (ja) 2011-06-16
JP5746015B2 (ja) 2015-07-08
EP2262772B8 (en) 2013-03-13
IL208103A0 (en) 2010-12-30
KR101325237B1 (ko) 2013-11-04
KR20100132038A (ko) 2010-12-16
CN102131783A (zh) 2011-07-20
EP2262772A1 (en) 2010-12-22
EP2262772B1 (en) 2012-07-18
IL208103A (en) 2015-08-31
RU2010146474A (ru) 2012-05-27
US20110092503A1 (en) 2011-04-21
ES2391373T3 (es) 2012-11-23
WO2009127417A1 (en) 2009-10-22
US9206130B2 (en) 2015-12-08
MX2010011224A (es) 2011-02-25
AU2009237938A1 (en) 2009-10-22

Similar Documents

Publication Publication Date Title
EP2262772B1 (en) Quinoline derivatives as axl kinase inhibitors
EP1415987B1 (en) Nitrogenous aromatic ring compounds as anti cancer agents
ES2868355T3 (es) Inhibidores del bromodominio
TWI473792B (zh) New quinoline compounds and their use
CA2909310A1 (en) Quinazolines and azaquinazolines as dual inhibitors of ras/raf/mek/erk and pi3k/akt/pten/mtor pathways
CN107098846B (zh) N-酰基磺酰胺类FBPase抑制剂、其制备方法、药物组合物及用途
WO2018145621A1 (zh) 喹啉类化合物、其制备方法及其医药用途
WO2015188747A1 (zh) 作为egfr抑制剂的苯基取代的三嗪类化合物及其应用
CN106478606B (zh) N-取代吲哚类衍生物及其应用
WO2013013614A1 (zh) 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用
WO2017005137A1 (zh) 喹唑啉类化合物、其中间体、制备方法、药物组合物和应用
CN107056755B (zh) 五元杂环酰胺类wnt通路抑制剂
CN113880772B (zh) 一类cdk激酶抑制剂及其应用
CA2603125A1 (en) Thienopyridine derivative, quinoline derivatives,and quinazoline derivatives, having c-met autophosphorylation inhibiting activity
ES2334708T3 (es) (3,4-dihidro-quinazolin-2-il)-(2-ariloxi-etil)-aminas que tienen una actividad sobre el receptor 5-ht.
BRPI0812816B1 (pt) Compostos derivados de sulfonil-quinolina, ligantes com preferência para subtipo de receptor mglur1 e mglur5, processos para a preparação dos referidos compostos, formulação farmacêutica compreendedo os referidos compostos e uso dos mesmos
TW201934547A (zh) 一種嘧啶類化合物、其製備方法及其醫藥用途
WO2023061051A1 (zh) 一种磺酰胺类usp8抑制剂及其应用
CN102558144A (zh) 一种芳基脲衍生物
HK1156952A (en) Quinoline derivatives as axl kinase inhibitors
WO2015043487A1 (zh) 喹唑啉类化合物及其制备方法与应用
CN104177312B (zh) 一种含硒化合物及其医药用途
CN105263926B (zh) 苯并噻吩化合物
CN117343046A (zh) 一种新型3-氧代-4-取代芳基-3,4-二氢吡嗪-2-甲酰胺类化合物及其应用
WO2025067486A1 (zh) 一类喹啉酮化合物、其制备方法和用途

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130416